Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTINCOL: Tinzaparin for VTE Prophylaxis in mCRC
NCT05625932Phase 3Completed
- Sponsor
- Galician Research Group on Digestive Tumors
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tinzaparin in venous thromboembolism (VTE), sponsored by Galician Research Group on Digestive Tumors. Started Mar 2023; status: completed.
02
Drugs
tinzaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05625932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625932.